Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The DNA polymerase alpha-primase complex interface with Minichromosome maintenance protein 10 (MCM10) and WD repeat and HMG-box DNA-binding protein 1 (WDHD1) is a critical regulatory junction within the eukaryotic replisome (Villa et al., 2014, Nature). This interface is essential for the recruitment and stabilization of the Pol alpha-primase complex at the replication fork, where it initiates DNA synthesis by producing RNA-DNA primers (Ricke and Bielinsky, 2004, J Biol Chem). WDHD1 (also known as CTF4) acts as a structural hub that couples the CMG helicase to Pol alpha, while MCM10 is required for helicase activation and the coordination of polymerase activity (Zhu et al., 2007, J Biol Chem). In many human cancers, such as breast and lung carcinoma, these proteins are overexpressed to facilitate rapid cell division, making the interface a promising target for anti-proliferative therapies (Baxley and Bielinsky, 2017, Genes). Disrupting these protein-protein interactions (PPIs) can trigger replication stress, DNA damage, and apoptosis, specifically in cells with high replication demands. Although no drugs targeting this specific interface are currently FDA-approved, research into small-molecule inhibitors and peptidomimetics is ongoing to exploit this vulnerability in oncology.
Inhibition of protein-protein interaction (PPI) to disrupt the recruitment of DNA polymerase alpha to the replication fork, preventing primer synthesis and inducing replication stress.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA polymerase alpha-primase complex interface with Minichromosome maintenance protein 10 (MCM10) and WD repeat and HMG-box DNA-binding protein 1 (WDHD1) (Pol alpha-MCM10-WDHD1 interface).